Phenolic Amides Are Potent Inhibitors of De Novo Nucleotide Biosynthesis. 2015

Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
Graduate Program in Cellular and Molecular Biology, University of Wisconsin-Madison, Madison, Wisconsin, USA Department of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, USA Great Lake Bioenergy Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.

An outstanding challenge toward efficient production of biofuels and value-added chemicals from plant biomass is the impact that lignocellulose-derived inhibitors have on microbial fermentations. Elucidating the mechanisms that underlie their toxicity is critical for developing strategies to overcome them. Here, using Escherichia coli as a model system, we investigated the metabolic effects and toxicity mechanisms of feruloyl amide and coumaroyl amide, the predominant phenolic compounds in ammonia-pretreated biomass hydrolysates. Using metabolomics, isotope tracers, and biochemical assays, we showed that these two phenolic amides act as potent and fast-acting inhibitors of purine and pyrimidine biosynthetic pathways. Feruloyl or coumaroyl amide exposure leads to (i) a rapid buildup of 5-phosphoribosyl-1-pyrophosphate (PRPP), a key precursor in nucleotide biosynthesis, (ii) a rapid decrease in the levels of pyrimidine biosynthetic intermediates, and (iii) a long-term generalized decrease in nucleotide and deoxynucleotide levels. Tracer experiments using (13)C-labeled sugars and [(15)N]ammonia demonstrated that carbon and nitrogen fluxes into nucleotides and deoxynucleotides are inhibited by these phenolic amides. We found that these effects are mediated via direct inhibition of glutamine amidotransferases that participate in nucleotide biosynthetic pathways. In particular, feruloyl amide is a competitive inhibitor of glutamine PRPP amidotransferase (PurF), which catalyzes the first committed step in de novo purine biosynthesis. Finally, external nucleoside supplementation prevents phenolic amide-mediated growth inhibition by allowing nucleotide biosynthesis via salvage pathways. The results presented here will help in the development of strategies to overcome toxicity of phenolic compounds and facilitate engineering of more efficient microbial producers of biofuels and chemicals.

UI MeSH Term Description Entries
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D000582 Amidophosphoribosyltransferase An enzyme, involved in the early steps of purine nucleotide biosynthesis, that catalyzes the formation of 5-phosphoribosylamine from glutamine and phosphoribosylpyrophosphate. EC 2.4.2.14. Glutamine Phosphoribosyl Pyrophosphate Amidotransferase,Phosphoribosyl Pyrophosphate Amidotransferase,Glutamine-Amidophosphoribosyltransferase,Phosphoribosyldiphosphate 5-Amidotransferase,5-Amidotransferase, Phosphoribosyldiphosphate,Amidotransferase, Phosphoribosyl Pyrophosphate,Glutamine Amidophosphoribosyltransferase,Phosphoribosyldiphosphate 5 Amidotransferase,Pyrophosphate Amidotransferase, Phosphoribosyl
D053898 Biosynthetic Pathways Sets of enzymatic reactions occurring in organisms and that form biochemicals by making new covalent bonds. Biosynthetic Pathway,Pathway, Biosynthetic,Pathways, Biosynthetic
D019800 Phenol An antiseptic and disinfectant aromatic alcohol. Carbol,Carbolic Acid,Hydroxybenzene,Phenol, Sodium Salt,Phenolate Sodium,Sodium Phenolate,Phenolate, Sodium
D029968 Escherichia coli Proteins Proteins obtained from ESCHERICHIA COLI. E coli Proteins

Related Publications

Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
November 2002, Accounts of chemical research,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
January 1992, Progress in nucleic acid research and molecular biology,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
January 1990, Medicinal research reviews,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
December 1989, AIDS research and human retroviruses,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
November 1968, Cancer chemotherapy reports. Part 2,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
July 1986, Kidney international,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
January 1991, Cancer chemotherapy and pharmacology,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
April 1976, Biochemical pharmacology,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
January 1993, Advances in lipid research,
Tippapha Pisithkul, and Tyler B Jacobson, and Thomas J O'Brien, and David M Stevenson, and Daniel Amador-Noguez
February 2009, Current opinion in genetics & development,
Copied contents to your clipboard!